Life's A Musical For Martin Shkreli
Executive Summary
The absurdity that's surrounded former drug company CEO Martin Shkreli, who has been indicted on eight federal charges, including securities fraud, has been made into a New York musical – really!
You may also be interested in...
Retrophin Bolsters Portfolio With Orphan Technologies Buyout
The rare disease-focused firm will pay $90m up front to acquire Orphan Technologies and its Phase I/II enzyme replacement therapy for homocystinuria. Earnouts up to $427m are possible as well.
Retrophin's Focus Shifts After Phase III PKAN Drug's Failure
Fosmetpantotenate missed all endpoints in a Phase III trial, so Retrophin will shelve the candidate for the rare disease PKAN. Now, the biotech turns focus to Phase III sparsentan in a pair of indications.
Oops, He Did It Again – Another Charge Against Shkreli
Prosecutors unsealed an additional charge of conspiracy to commit securities fraud against Martin Shkreli – infamously known for hiking up the price of a toxoplasmosis medicine by 5,000% – bringing the total number of criminal counts against the former drug company CEO to eight.